Novavax Announces Management Promotions to Support Expanded Clinical Activity in 2014
ROCKVILLE, Md., Jan. 13, 2014 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX)
announced a number of promotions within its clinical operations group in
preparation for expanded clinical trial activities in 2014 and 2015.
Gregory M. Glenn, M.D. has been named Senior Vice President, Research and
Development. Dr. Glenn joined Novavax in July 2010 as Senior Vice President,
Chief Scientific Officer and in January 2011, was named Senior Vice President,
Chief Medical Officer. Dr. Glenn has 22 years in translational vaccine
development, including discovery, preclinical and clinical development in viral,
bacterial and parasitic vaccines and has authored over 65 peer-reviewed
publications. Prior to joining the Company, Dr. Glenn was the Chief Scientific
Officer and founder of Iomai Corporation, which was acquired by Intercell in
2008. He began his vaccine research career at the Walter Reed Army Institute of
Research, was board-certified in pediatrics and received his medical degree from
Oral Roberts University School of Medicine.
Louis F. Fries III, M.D. has been named Vice President, Chief Medical Officer.
Dr. Fries was Vice President of Clinical and Medical Affairs when he joined
Novavax in April of 2011. He had formerly served as Director of Clinical
Development for GSK biologicals following the acquisition of ID Biomedical by
GSK in 2005, and previously had been Vice President of Clinical and Regulatory
Affairs at ID Biomedical. Dr. Fries received his medical degree from Duke
University, has nearly 25 years of experience in the clinical testing and
development of human vaccines, and has authored over 60 peer-reviewed
The Company also announced the appointment of D. Nigel Thomas, Ph.D. to Vice
President, Clinical Operations. Dr. Thomas also joined the company in April of
2011 as Executive Director, Clinical Operations. Most recently, Dr. Thomas had
been Clinical Operations Director at Iomai beginning in 2006 and through its
acquisition by Intercell. He has previously held a variety of clinical operation
positions in the Biotechnology and CRO industry. Dr. Thomas received his Ph.D.
in Biochemistry & Physiology from the University of Reading in the United
Kingdom and has overseen numerous vaccine, drug and medical device clinical
trials including global Phase 2 and Phase 3 clinical trials for vaccines.
"I am very pleased to announce these promotions within the Novavax management
team. Over the last couple years, Novavax has consistently demonstrated the
ability to deliver on our clinical trials, thanks in large part to the work of
Greg, Lou and Nigel. Novavax' ability to bring important, and in the case of our
RSV and our H7N9 influenza trials, industry-changing, clinical results has
positioned us for a critical couple of years of expanded clinical trial
activity," said Stanley C. Erck, President and CEO.
Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage biopharmaceutical company
creating novel vaccines and vaccine adjuvants to address a broad range of
infectious diseases worldwide. Using innovative proprietary recombinant protein
nanoparticle vaccine technology, the company produces vaccine candidates to
efficiently and effectively respond to both known and newly emergent diseases.
Additional information about Novavax is available on the company's website,
CONTACT: Barclay A. Phillips
SVP, Chief Financial Officer and Treasurer
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Novavax, Inc. via GlobeNewswire